Figure 1 (Desvenlafaxine Figure1)
Desvenlafaxine Tablet, Extended Release
Product Images NDC 50090-5293
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine (NDC 50090-5293). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 2 (Desvenlafaxine Figure2)
Change due to PK (Geometric mean ratio (30% Cl): This text appears to be related to pharmacokinetics (PK) and the effect of CYP3A4 inhibitors on drug metabolism. It mentions ketoconazole as an example. The text also includes information about changes in the Cmax (maximum concentration) and AUC (area under the curve) values, expressed as geometric mean ratios with confidence intervals (30% Cl). It seems to be discussing the change in pharmacokinetic parameters relative to a reference.*
Figure 3 (Desvenlafaxine Figure3)
Figure 4 (Desvenlafaxine Image4)
Estimated proportion of patients with relapse (%): 10. Time to relapse (days from randomization): Desvenlafarine Extended-Release Tablets 50mg - Placebo. Maximum value on the graph: 200.*
Figure 5 (Desvenlafaxine Image5)
Structure (Desvenlafaxine Structure1)
Label Image (Lbl500905293)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
